News articles about Sangamo Therapeutics (NASDAQ:SGMO) have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sangamo Therapeutics earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 42.4997569709465 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern’s analysis:
- Why Sangamo Therapeutics Stock Soared 27% in January (finance.yahoo.com)
- Here’s Why Sangamo Therapeutics Rose as Much as 13.7% Today (fool.com)
- Here's Why Sangamo Therapeutics Rose as Much as 13.7% Today (finance.yahoo.com)
- Sangamo Therapeutics Inc (SGMO) VP Edward R. Conner Sells 5,000 Shares (americanbankingnews.com)
- Sangamo Therapeutics Presents Initial Safety Data from CHAMPIONS Genome Editing Study for MPS II at WORLDSymposium (finance.yahoo.com)
A number of research firms recently weighed in on SGMO. BidaskClub raised Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, January 24th. Jefferies Group restated a “buy” rating and issued a $18.00 price target on shares of Sangamo Therapeutics in a research note on Friday, October 13th. Piper Jaffray Companies upgraded Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 price target for the company in a research note on Wednesday, November 15th. Zacks Investment Research upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research note on Wednesday, November 15th. Finally, Barclays assumed coverage on Sangamo Therapeutics in a research note on Wednesday, November 22nd. They issued an “overweight” rating and a $20.00 price target for the company. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $18.83.
Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The business had revenue of $11.81 million during the quarter, compared to the consensus estimate of $10.37 million. During the same period in the prior year, the company earned ($0.27) EPS. Sangamo Therapeutics’s revenue for the quarter was up 333.0% on a year-over-year basis. analysts anticipate that Sangamo Therapeutics will post -0.73 EPS for the current year.
In other Sangamo Therapeutics news, Director Saira Ramasastry sold 5,000 shares of the company’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $14.67, for a total value of $73,350.00. Following the completion of the transaction, the director now owns 5,000 shares of the company’s stock, valued at approximately $73,350. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Steven J. Mento sold 11,520 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $20.59, for a total value of $237,196.80. Following the completion of the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $102,950. The disclosure for this sale can be found here. In the last ninety days, insiders sold 89,953 shares of company stock valued at $1,618,193. Insiders own 5.50% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://sportsperspectives.com/2018/02/09/sangamo-therapeutics-sgmo-given-daily-coverage-optimism-rating-of-0-19.html.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.